---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-112359"
form_type: "8-K"
ticker: "VYNE"
cik: "0001566044"
company_name: "VYNE Therapeutics Inc."
filed_at: "2023-10-30T23:59:59+00:00"
generated_at: "2026-06-09T05:56:31.253762+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# VYNE announces $88M PIPE funding and positive clinical data for VYN201 and VYN202

## Summary
- Raised $88M gross from PIPE led by Access Biotechnology, with participation from healthcare investors.
- Phase 1b VYN201 vitiligo trial: 1.0% cohort 30.3% mean F-VASI reduction (p=0.0137), 2.0% cohort 39.0% (p=0.0077) vs 0.5%.
- VYN202 preclinical: 95% PASI reduction in psoriasis model; 71% reduction in rheumatoid arthritis signs/symptoms.
- Preliminary cash $15.5M as of Sep 30, 2023; with PIPE proceeds pro forma $103.7M.
- Next steps: Phase 2b VYN201 in vitiligo in 1H2024; Phase 1a VYN202 trial expected Q1 2024.

## SEC filing metadata
- accession: 0001104659-23-112359
- form_type: 8-K
- ticker: VYNE
- cik: 0001566044
- company_name: VYNE Therapeutics Inc.
- filed_at: 2023-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 1.02, 2.02, 3.02, 5.08, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/tm2329331d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-112359
- JSON: https://secwatch.observer/filing/0001104659-23-112359.json
- Plain text: https://secwatch.observer/filing/0001104659-23-112359.txt

## Key facts
- Material Agreements
  VYNE Therapeutics Inc. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $88.2 million (effective 2023-10-27).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and other accredited investors
  - Value: $88.2 million
  - Effective: 2023-10-27
  source text: On October 27, 2023, VYNE Therapeutics Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement transaction
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm
- Material Agreements
  VYNE Therapeutics Inc. terminated Purchase Agreement with Lincoln Park Capital Fund, LLC (effective 2023-10-30).
  - Action: termination
  - Agreement: equity purchase
  - Counterparty: Lincoln Park Capital Fund, LLC
  - Effective: 2023-10-30
  source text: On October 30, 2023, the Company delivered a notice of termination to Lincoln Park terminating the Purchase Agreement effective as of one business day following delivery of notice.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1566044/000110465923112359/0001104659-23-112359-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.